Bengaluru-based diagnostics platform Orange Health Labs has successfully secured approximately $30 million (Rs 277 crore) in its Series C funding round. The investment was led by Iron Pillar India and saw participation from both new and existing backers. This capital infusion, occurring 18 months after its last round, is set to accelerate the company's expansion plans in the competitive health-tech market.
Investment Round Specifics
According to regulatory filings, the company's board approved a special resolution to facilitate this capital raise. The transaction involves the issuance of 4,579,270 Series C compulsorily convertible preference shares to the participating investors. Each share was priced at Rs 604.72, culminating in the total funding amount of Rs 277 crore.
Iron Pillar India spearheaded the investment with a significant commitment of Rs 156 crore, or about $16 million. The round also welcomed new investors, including Crescent Enterprises, which contributed Rs 37.7 crore. Good Capital and Paramark Frontier Fund further bolstered the funding with investments of Rs 15.5 crore and Rs 37 crore, respectively.
Continued Support and Valuation Growth
The funding round demonstrated strong continued confidence from the company's existing investors. Bertelsmann participated with an investment of Rs 21.8 crore, while Accel India and General Catalyst contributed Rs 8 crore and Rs 1.8 crore. This sustained support underscores the belief in Orange Health Labs' long-term vision and operational strategy.
This latest infusion of capital places Orange Health Labs at a post-money valuation of approximately Rs 1,950 crore, which is equivalent to about $205 million. Following the allotment, Accel India will maintain its position as the largest external shareholder with a 15.49% stake. Lead investor Iron Pillar India will officially join the company's cap table, securing an 8.0% ownership stake.
Company Trajectory and Financials
Founded in 2020 by Dhruv Gupta and Tarun Bhambra, Orange Health Labs has quickly established itself in the diagnostics sector. The startup operates a full-stack platform offering on-demand health testing services directly to consumers. Its core service includes convenient at-home sample collection for a wide range of routine diagnostic tests.
Prior to this Series C round, the company had already raised close to $50 million to fuel its initial growth. Its funding journey includes a notable $25 million Series B round in 2022, co-led by General Catalyst and Bertelsmann India Investments. More recently, it secured $12 million in 2024 in a round led by the Amazon Sambhav Venture Fund.
While the company has not yet filed its annual financial results for the fiscal year 2026, its performance in FY25 provides some insight. During that period, Orange Health Labs recorded a revenue of Rs 84 crore. However, the company also reported a loss of Rs 81 crore as it continued to invest in scaling its operations.
This substantial Series C funding marks a pivotal moment for Orange Health Labs, equipping it with the necessary resources to enhance its service offerings and expand its market reach. The diverse investor base, combining new and existing partners, signals strong market validation for its on-demand diagnostics model. The capital will be instrumental as the company navigates its next phase of growth in India's burgeoning health-tech landscape.